Xinqi Huang
Xuefeng Pan1†
Xiao Cen- 1State Key Laboratory of Oral Diseases & National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, China
- 2Hospital of Stomatology, Zunyi Medical University, Zunyi, China
The number of people suffering from temporomandibular joint osteoarthritis (TMJOA) has been increasing. TMJOA cause joint noise, pain on TMJ and/or masticatory muscles, and restricted mandibular movement, which disturb eating, laughing and conversation, and impose serious lifestyle impediments. Chondrocyte apoptosis, extracellular matrix degradation, synovitis, and subchondral bone remodeling are the main pathological features of TMJOA. Various drug delivery systems are developed to controlled release at specific activation sites with high bioactivity and inhibit rapid dilution to enable long-term therapeutic response, which present great potential for the treatment of TMJOA. This review focuses on recently developed drug delivery systems by different administration in the TMJOA treatment, and summarizes their effects, duration, safety, and limitations, which would pave the way for development of TMJOA therapy.
1 Introduction
Temporomandibular joint (TMJ) is a synovial joint responsible for complicated mandibular movement and various normal function (e.g., eating, laughing, and conversation). As TMJ is sensitive to mechanical force, excessive loading on normal joint or normal loading on impaired joint could both cause the destruction of joint structure, and eventually progress into TMJ osteoarthritis (OA). Although the etiology of TMJOA is not fully understood, yet several factors are commonly considered, including malocclusion, mental factors, and abnormal maxillofacial muscles. With the three major symptoms of TMJOA (i.e., joint noise, pain, and restricted mandibular movement), the life quality and normal function of patients will be severely affected. Pathologically, cartilage extracellular matrix is degraded by matrix metalloproteinases (MMPs), a disintegrin and metalloprotease with thrombospondin motifs (ADAMTS), and chondrocyte apoptosis in affected cartilage tissue; under the mechanical and inflammatory microenvironment, subchondral bone becomes thinner in the early stage while bone sclerosis and osteophyte formation are in the late stage; synovitis are also the hallmarks of TMJOA and further exacerbate the local inflammatory environment.
Currently, the common drugs introduced to treat OA clinically include glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), viscosupplements, and other traditional drugs through oral administration, intra-articular injections, and/or transdermal patch. However, these methods can only relieve inflammatory symptoms, but barely inhibit the progress of OA or reverse the course and cure OA. Furthermore, the drugs also have the disadvantages of being easily eliminated and the risk of causing adverse reactions.
Herein, this review focuses on recently developed drug delivery systems by different administration in the TMJOA treatment (Figure 1), and summarizes their effects, duration, safety, and limitations.
FIGURE 1. Schematic of various nanoparticles and administration routes in the TMJOA treatment.
2 Intra-articular drug delivery systems
IA injection, which delivers drugs to the articular cavity directly, is the most widely used administration mode for the treatment of OA. However, after small- and large-molecule drugs enter the TMJ cavity, they are easily cleaved by synovial capillaries and lymphatics, which results in failure of the drug to reach a therapeutic dose in the articular cavity. Frequent and multiple administrations are utilized to solve this challenge currently, which cause pain, subcutaneous atrophy, increase risk of infection, joint disease progression, and decrease the patient compliance (Ta and Dionne, 2004).
Drug delivery systems can suspend in the joint cavity, slowly releasing the drug into the cavity. In some condition, synovial tissue can retain the drug delivery systems, and the drugs are released directly into the articular capsule and influence immune cells or fibroblasts. Therefore, sustained-release drug delivery systems are needed to extend the residence time to reduce adverse effect caused by frequent injections and large dose, and improve the efficacy of these drugs in the articular cavity. Various drug delivery systems for IA injection have been developed to enhance the bioavailability and prolong the circulation time to improve the efficacy of drugs, which are summarized in this section (Table 1).
TABLE 1. Different drug delivery systems for intra-articular injection.
2.1 Lipid nanoparticle systems
Lipid nanoparticles are composed of cationic or neutral lipids, cholesterol, and polyethylene glycol (PEG)-lipids, which simulate cell membranes with a diameter of about 100 nm. Lipid nanoparticles are widely used for non-viral drug delivery, as they have a large number of advantages including high encapsulation efficiency, strong tissue permeability, low cytotoxicity and immunogenicity (Cullis & Hope, 2017).
Owing to the amphoteric properties of lipids, lipid nanoparticle systems can not only encapsulate hydrophilic drugs in the interior aqueous space, such as water-soluble dexamethasone phosphate (Anderson et al., 2010), but also hydrophobic drugs inserted in the hydrophobic region of the bilayer, such as kartogenin (KGN) (Yang et al., 2020). Additionally, diverse lipids species and ratios can be selected to easily fine-tune the physicochemical properties of lipid nanoparticle systems. The outer surface is also capable of functional modifications to attain long-term stabilized and targeted drug-delivery carriers, and achieve diagnostic and therapeutic platforms (Al-Jamal et al., 2011; Namiki et al., 2011).
Naproxen is one kind of nonsteroidal anti-inflammatory drugs (NSAIDs), which serves as the inhibitor of cyclooxygenase-1 (COX-1) and COX-2, and thus naproxen is commonly prescribed for the treatment of TMJOA patients to relieve symptoms and restore function (Cigerim and Kaplan, 2020). Encapsulation of naproxen into lipid nanoparticles designed for administration into TMJ has been successfully reported, which is capable to reduce the administration frequency and improve the therapeutic efficacy (Guilherme et al., 2019). This work develops an optimized nanostructured lipid carrier which is composed of 2% Pluronic® F68 (P68) and 20% total lipids (70/30 solid lipid/liquid lipid), and its encapsulation efficiency of naproxen was 99.8% ± 0.2%. This naproxen-loaded system can limit the leucocyte migration to the inflamed rat TMJs and downregulate inflammatory cytokines levels for 10 days after application (Guilherme et al., 2019). This impressive therapeutic effect suggests the sustained release profile of naproxen provided by the nanostructured lipid carrier can prolong the anti-inflammatory effect after one application, and multiple administrations will not be required, which can increase the patient compliance to the treatment and reduce naproxen side effects. Moreover, the nanostructured lipid carrier is composed of the lipids with good biocompatible nature, and thus it may decrease drug local toxicity and subsequent inflammation of injected sites at TMJ (Tamjidi et al., 2013).
2.2 Poly (lactic acid-co-glycolic) acid-based system
Poly (lactic-co-glycolic) acid (PLGA) is a kind of injectable, degradable, and functional polymer organic compound. PLGA has good biocompatibility, performance of encapsulation and film-forming capacity, and thus it is widely applied to the development of new pharmaceuticals and medical engineering materials (Ding and Zhu, 2018). Mountziaris et al. (2010) produced PLGA microparticles by an established double-emulsion solvent extraction technique, and investigated in vivo biocompatibility of these PLGA microparticles for intra-articular drug sustained release in the TMJs. Computerized meal pattern showed that bilateral intra-articular injection of 15, 30, or 50 mg/ml PLGA microparticles did not induce TMJ pain or nociception over 6 days. No additional tissue reaction but a mild inflammatory infiltrate was observed in the 15, 30, or 50 mg/ml PLGA groups, compared with injection with carrier solution alone.
Parecoxib is a highly selective inhibitor of COX-2, which suppresses prostaglandin (PG) synthesis and alleviates chronic inflammatory conditions such as OA. Parecoxib-loaded hyaluronic acid (HA)-PLGA microspheres are fabricated for sustained release in TMJ synovitis therapy (Zhu et al., 2021). The loading rate of parecoxib in this delivery system reaches 17.12%–20.95%, while its drug release tests in vitro show a slow sustained release over 28 days. Treatment with parecoxib-HA-PLGA microspheres declined inflammatory gene expression in synovial cells in vitro, and injection of these microspheres can downregulate expression levels of inflammatory cytokines for more than 2 weeks in rat models. Some studies encapsulated 15d-PGJ2, which is a natural ligand for peroxisome proliferators-activated receptor-γ (PPARγ), into PLGA to develop nanocapsules for the therapy of TMJ pain (Clemente-Napimoga et al., 2012). Compared with injection of 15d-PGJ2 only, the intra-articular injection of 15d-PGJ2-PLGA nanocapsules could decrease the release of IL-1β cytokine, and nociceptive behavioral response was also reduced significantly in the formalin-induced rat models.
After the first therapeutic small interfering RNA (siRNA) (ONPATTRO™) was approved by United States Food and Drug Administration (FDA) in 2018, many biopharmaceutical and biotech companies are developing RNA-based therapies which are in different stages of drug development pipeline (Bai et al., 2020; Kulkarni et al., 2021; J. Yang et al., 2020; Z. Yang et al., 2020). The RNA drugs include short interfering RNA (siRNA), oligonucleotides, messenger RNA (mRNA), microRNA (miRNA), RNA aptamers and so on, and RNA application involves mediating transcriptional activation, encoding disease-related proteins, and regulating expression of specific genes and proteins, which present great potential for the treatment of OA. However, the clinical application of RNA therapeutics remains a challenge. The action sites of RNAs are mostly intracellular, while RNA molecules are hydrophilic and negatively charged as well as have high molecular weights, which make it difficult for RNAs to cross cell membrane into cytoplasm. Additionally, RNAs are sensitive to ubiquitous RNases. It is reported that unprotected RNAs have an extremely short metabolic or systemic half-life (e.g., less than 7 min) (Soutschek et al., 2004). Therefore, delivery systems are critical for the development and application of RNA drugs.
Matrix metalloproteinase 13 (MMP13) can degrade type II collagen which is the vital cartilage structural protein, and si-MMP13 is reported as a disease modifying therapy for OA (Yang et al., 2020). Shape-defined PLGA microplates are established to carry si-MMP13 (Bedingfield et al., 2021; Bedingfield et al., 2021.). It is showed that PLGA-based microplates maintained si-MMP13 in the joint cavity longer significantly, and injection with these microplates against MMP13 maintained potent knockdown of MMP13 gene expression and protein production in the joint tissues over 28 days. Therefore, PLGA is a promising biomaterial to be utilized in sustained-release RNA delivery systems for the treatment of TMJOA. PLGA-based systems in delivering siRNA are usually in conjunction with polyethylenimine (PEI). PEI is a kind of cationic polymeric transfection agents. The incorporation of PEI can protect siRNAs from degradation by extracellular nucleases, and balance the negative charge of siRNAs and thus enhance cellular uptake (Gary et al., 2007). A study evaluated several important parameters for siRNA-loaded PLGA nanoparticles and indicated the necessity of transfection agents in gene silencing (Jensen et al., 2010). PEI can also increase the ratio of encapsulated siRNA, and transfection efficiency of siRNA-PEI-PLGA microparticles was higher than siRNA-PLGA microparticles (Murata et al., 2008; Wang et al., 2017). Some studies develop PLGA-based microparticle formulations to carry anti-inflammatory RNAs to extend their residence time in the TMJ cavity (Mountziaris et al., 2011). Tumor necrosis factor-α (TNF-α) is a kind of pro-inflammatory cytokines, which is expressed highly in the arthritic TMJs (Bi et al., 2022). Mountziaris et al. (2011) developed a TNF-α siRNA-PEI-PLGA microparticles and investigated their release kinetics. This study showed that PEI could decrease burst release of TNF-α siRNA and serve as a porogen to facilitate the process of later release, which provided clues of a sustained release system for the treatment of TMJ degeneration. Fragment crystallizable gamma receptor III (FcγRIII) is a member of the fragment crystallizable (Fc) receptor family, which prefers to bind with immunoglobulin type G (IgG) and then triggers inflammation (Clay et al., 2018). The FcγRIII siRNA-PEI-loaded PLGA microparticles displayed sustained release of FcγRIII siRNA and PEI over 28 days, and these microparticles also decreased the expression levels of inflammatory cytokines in rat TMJs and reduced changes of meal pattern for 9 days (Mountziaris et al., 2012). Another study reported that a single intra-articular injection of PEI- FcγRIII siRNA can downregulate the expression of FcγRIII in the TMJ tissue and decrease the nociceptive response in the TMJOA rats for 2 days (Kramer et al., 2010). However, this study found that the same dosage of naked FcγRIII siRNA and PEI complexed FcγRIII siRNA had the same anti-inflammatory effect on the inflamed TMJs, which suggested PEI might have no improvement on the transfection efficiency of siRNAs. Therefore, future studies are needed to verify the effect of PEI on siRNA delivery PLGA system and the specific transfection protocol for TMJs. Additionally, these studies utilized CFA-induced TMJ inflammation in the rat model, whose duration is relatively short (Feng et al., 2021), and thus the evaluations of controlled release pattern and inflammatory inhibition of siRNA delivery PLGA-based system are limited. Further studied utilizing TMJOA models with long-lasting inflammation are needed to address this limitation.
2.3 Chitosan-based system
Chitosan is a linear amino-polysaccharide with good biocompatible and biodegradable properties, and it has a similar chemical structure to glycosaminoglycans which are the main components of cartilage (Kang et al., 2014). Chitosan can be fabricated as fibers, membranes, nanoparticles, and hydrogels. Moreover, chitosan presents many biological properties, such as antibacterial, antifungal, antioxidant, anti-inflammatory, antihyperglycemic, analgesic, and mucoadhesive properties, and thus chitosan-based formulations are widely applied to medicine and dentistry (Derwich et al., 2022). A retrospective cohort clinical study showed three intra-articular injections of chitosan for the patients with TMJOA can increase maximal interincisal opening, reduce pain intensity, and relieve TMJ sounds, which is not better than that of autologous platelet-rich plasma (PRP) (Li et al., 2021). However, complications related to the intra-articular injections, such as pain and swelling in the area of TMJ, are only observed in the patients receiving PRP injection but not in those receiving chitosan injection (Li et al., 2021). These results suggest intra-articular injections of chitosan only is safe but not effective enough for the treatment of TMJOA. Chitosan is usually obtained from chitin in an incomplete deacetylation process, which make chitosan contain acetamide groups and be positively charged in weak acidic solution. Therefore, the cationic chitosan-based system can passively target to cartilage via electrostatic attraction, which shows the possibility to develop the drug delivery systems based on chitosan for osteoarthritic joints (Brown et al., 2020).
HA is also a kind of polysaccharides, which is with similar biochemical structures to chitosan. It is known that HA can restore the rheology and visco-elastic properties of the components of joints, present anti-inflammatory and antinociceptive abilities, and protect the cartilage. HA injections, which are called as visco-supplementation treatment, are beneficial to joint stabilization, lubrication, and nutrition, and thus HA injections are proposed as first-line choice for TMJOA (Ferreira et al., 2018). However, HA can be cleared away rapidly from the joint after injection, while frequent injections can result in partial bone necrosis of the articular tubercle and increase the risk of bone degeneration because of repeated microtrauma (Sato and Kawamura, 2006); Talaat et al. (2016) developed a chitosan-based thermosensitive hydrogel for controlled release of HA in the temporomandibular joints. Chitosan aqueous solution is mixed with β-glycerophosphate to prevent immediate gelation and achieve thermosensitive hydrogels, and a Chitosan:β-glycerophosphate ratio of 1:25 is chosen to carry HA in this study. The results show that this chitosan-based thermosensitive hydrogel can retain more than one-third of injected HA in the TMJs after 7 days, which is much more than the controls (injection with HA solution). Therefore, this chitosan-based formulation is a promising controlled release system of HA, and avoid frequent injection of HA for TMJOA therapy. Further studies are required to assess the efficiency of this chitosan-based formulation for longer durations, and optimize release of HA at different time point for better TMJ therapeutics.
2.4 Mesoporous silica nanoparticles-based system
Mesoporous silica nanoparticles (MSNs) have gained more and more attention for the promising biomedical applications in the past decade (Tang et al., 2012). Featured with the high surface area and abundant surface functionalization, tailored pore size and volume, and stable framework, MSNs serve as excellent drug drivers with rapid development (Tang et al., 2012; Li et al., 2019). MSNs can be utilized as a local treatment, carrying osteostatin and SOST siRNA to exhibit anti-osteoporotic effects via bone marrow injections (Mora-Raimundo et al., 2019). Additionally, MSNs-based system can also be designed and used as a systemic treatment for osteoporosis. For example, MSNs functionalized with alendronate can deliver biomolecules to bone through intravenous administration (Mora-Raimundo et al., 2021).
MSNs with a core-cone structure (MSN-CC) present large pore size and high pore volume, which have demonstrated the high loading capacity of proteins with large molecular weights and showed the ability of cellular delivery of active large proteins (Xu et al., 2015). Li et al. (2019) engineer MSN-CC with PEI modification (MSN-CC-PEI) to load and drive hyaluronan synthase type 2 (HAS2) to synoviocytes in the TMJs. HAS2 is a large-sized protein which produces HA with high molecular weight and maintains the normal functions of synovial fluid (Ishizuka et al., 2019). It is showed that around 82.1% of total MSN-CC-PEI enter and deliver HAS2 into the cells, and HAS2-loaded MSN-CC-PEI can escape from endosome and release HAS2 in cytoplasm of synoviocytes to synthesis HA with high molecular weight (Li et al., 2019). Notably, one-shot administration of HAS2-loaded MSN-CC-PEI maintains the high HAS2 activity and inhibits the synovial inflammation for more than 3 weeks in the rat TMJOA inflammation model, and also shows good ability of TMJ bone defects repairment after 12 weeks in another rat model (Li et al., 2019). This MSN-based nanocarrier offers an efficient and easy-to-use approach for TMJOA management.
2.5 Poloxamer micellar system
Poloxamers is a nonionic triblock copolymer consisting of poly (propylene oxide) (PPO) and poly (ethylene oxide) (PEO) arranged in an ABA-like basic structure (i.e., the central hydrophobic units of PPO flanked by two hydrophilic chains of PEO). Physicochemical changes in temperature, pH, or ionic concentration can trigger self-assemble of poloxamers and formation of cross-linked hydrogels by micellar rearrangement. Additionally, different kinds of poloxamers can be associated to form binary systems to develop new carrier systems with different biopharmaceutics properties.
Poloxamer 407, also referred to as Pluronic F-127, has good biocompatibility and is widely used as a drug delivery vehicle (Moura et al., 2020; Liao et al., 2021). It is reported that PEO-PPO-PEO hydrogel Pluronic F127 can load recombinant adeno-associated virus (rAAV) vectors overexpressing the chondrogenic sox9 transcription factor (rAAV-FLAG-hsox9), which form an injectable and thermosensitive therapeutic hydrogel capable of sustained release of rAAV-FLAG-hsox9 (Madry et al., 2020). This rAAV-FLAG-hsox9/PEO-PPO-PEO can repair the cartilage with arranged collagen fibers and protect the subchondral bone plates from bone loss (Madry et al., 2020). Zhang et al. (2021) utilize poloxamer 407 and poloxamer 188 to prepare a glucosamine-encapsulated thermoresponsive hydrogel. The sol–gel transition temperature of this hydrogel is approximately 35°C and this hydrogel also presents a slow release of glucosamine in vitro. Intra-articular administration of glucosamine-loaded thermoresponsive hydrogel in rabbits with OA can reduce the degree of swelling, inhibit release of inflammatory factors, and repair the damaged cartilage. In addition, poloxamer 407 is utilized to carry 15d-PGJ2 to manage inflammatory pain of TMJOA (Abdalla et al., 2020). It is showed that 15d-PGJ2-loaded poloxamer micellar system can relieve TMJ pain at lower concentrations and in a more sustained manner than free 15d-PGJ2.
3 Transdermal drug delivery systems
Transdermal drug delivery approaches can avoid first-pass metabolism, control the drug release rates over a prolonged time, and reduce the risk of systemic side effects (Morry et al., 2015). Skin also acts as a reservoir, which enables the diffusion of the penetrated drugs from skin continuously for a longer period and presents an opportunity of lower frequency of administration (Qu et al., 2022). As the stratum corneum (SC) layer of the skin is the capital barrier which limits the penetration of most drugs, many approaches have been adopted to disrupt the SC layer and increase skin permeability, including physical enhancers (iontophoresis, electroporation, sonophoresis, and microneedles), chemical enhancers (alcohol and peptide), and delivery vehicles (spherical nucleic acid and lipoplexes) (Ita 2017; Phatale et al., 2022; Qu et al., 2022). It is reported that transdermal drug delivery approaches enable topical drug delivery to the periarticular tissues of TMJs, which offer a painless and convenient platform to treat TMJOA-associated conditions (Figure 2 and Table 2).
FIGURE 2. Physical techniques of transdermal drug delivery for TMJOA.
TABLE 2. Different transdermal drug delivery systems for TMJOA.
3.1 Microneedles
Microneedles (MNs) patches are comprised of micron-scaled sharp projections, which can overcome SC resistance in a painless manner and transport of drugs into the skin with improved safety, efficacy, and bioavailability (Queiroz et al., 2020; Chen et al., 2022). One study evaluates the influence of MNs on 15d-PGJ2 transdermal delivery in a rat model of TMJ pain (Macedo et al., 2017). The results show that 15d-PGJ2 cream associated with MNs can hinder the release of pro-inflammatory cytokines and reduce the formalin-induced nociceptive behavior significantly, whose antinociceptive effects are more obvious and last longer than an intra-TMJ injection of 15d-PGJ2. Therefore, 15d-PGJ2 cream associated with MNs is a promising patient-friendly therapeutic method for pain management related to TMJOA. Similarly, another study coats MNs with tramadol, and finds that tramadol delivery via MNs produce more durable antinociceptive effects than intra-TMJ injection of tramadol (Abdalla et al., 2019). However, there is no coating on MN patches for controlling the cargo leakage, which results in burst release of cargoes at the beginning (Wang et al., 2020). This restricts the applications of MN-based drug delivery systems on longitudinal treatment, and thus various controlled delivery nanoparticals are expected to be applied to the MN platform for broadening the biomedical applications.
3.2 Electroporation
Electroporation is another physical enhancer used in transdermal drug delivery systems. Electroporation utilizes short (less than 1 s) and high voltage (50–500 V) pulses to cause electropermeabilization and enhance the electrophoretic mobility and molecular diffusivity (Blagus et al., 2013). The temporary aqueous pores in cell membranes alter the electrical conductivity of stratum corneum, and thus the skin barrier is overcome for drug penetration. It is reported that electroporation is utilized to deliver biomolecules of different lipophilicities and molecular weight through enhanced passive diffusion. A clinical study compares the effects of an electroporation-enhanced transdermal application of diclofenac sodium to a conventional intra-articular injection of corticosteroids on TMD associated pain (Tartaglia et al., 2020). The results show that the electroporation in transdermal delivery of diclofenac sodium decreases TMD-related pain levels, improves mouth opening and electromyography to normal values for 1 week after application, while the long-lasting effects are planned to evaluated in future.
4 Future outlooks
Oral administration and intra-articular injection are the most widely used routes in the TMJOA treatment. There are some novel drug delivery systems by intra-articular injection which release large or small biomolecules continually and controllable. They can decrease the clearance rate of biomolecules, reduce the inflammatory cytokines release, and promote the repair of cartilage defects effectively (Cao et al., 2021). Although some achievements have been made, there still remains some questions to be answered. For example, 1) can the drug delivery systems by intra-articular injection target more specifically to diseased sites during OA progress; 2) how about the long-term effect and 3) chronic toxicity of these delivery systems, as the studies now usually utilize the OA models with short duration.
By oral administration, the active ingredients reach TMJs via the circulatory system, which only allows a small amount of drug to the diseased cartilage and also faces problems including low bioavailability, gastrointestinal injury, and even liver and kidney damage (Raza et al., 2014; Cao et al., 2021). However, few studies have so far focused on the oral administration of drug delivery systems for TMJOA. As oral administration is a convenient and painless route without the need for doctors’ operation, it is significant to design and develop more TMJ-targeted oral drug delivery systems with a sustained release pattern and high bioavailability. Topical drug administration via transdermal delivery systems can allow drugs to cross skin barriers and remarkably reduce systemic toxicity and irritation (Li et al., 2021). However, most studies develop transdermal delivery systems for knee OA therapy, while only three studies from two labs utilize MN patches or electroporation to relieve TMJOA-related pain and jaw function restriction. Moreover, various controlled delivery nanoparticals are expected to be applied to the transdermal delivery platforms for broadening the biomedical applications in TMJOA therapy Prausnitz and Langer. (2008).
Author contributions
XC and ZZ: Conception and literature search. XH, XP, and XX: Manuscript writing and final approval. All authors contributed to the article and approved the submitted version.
Funding
This work was supported by National Natural Science Foundation of China (81900981), China Postdoctoral Science Foundation (2019M663530), Sichuan Science and Technology Program (2021YJ0149), Research and Development Foundation of West China Hospital of Stomatology (RD-02-202106), and Research Funding from West China School/Hospital of Stomatology Sichuan University (RCDWJS 2020-18).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
Abdalla, H. B., Jain, A. K., Napimoga, M. H., Clemente-Napimoga, J. T., and Gill, H. S. (2019). Microneedles coated with tramadol exhibit antinociceptive effect in a rat model of temporomandibular hypernociception. J. Pharmacol. Exp. Ther. 370 (3), 834–842. doi:10.1124/jpet.119.256750
Abdalla, H. B., Napimoga, M. H., Macedo, C. G., Bonfante, R., De Araujo, D. R., de Mello, N. F. S., et al. (2020). Poloxamer micellar system for intra-articular injection of 15-deoxy-(Δ12, 14)-prostaglandin J(2) with improved bioavailability and anti-inflammatory properties in the temporomandibular joint of rats. Int. J. Pharm. 583, 119383. doi:10.1016/j.ijpharm.2020.119383
Al-Jamal, W. T., and Kostarelos, K. (2011). Liposomes: From a clinically established drug delivery system to a nanoparticle platform for theranostic nanomedicine. Acc. Chem. Res. 44 (10), 1094–1104. doi:10.1021/ar200105p
Anderson, R., Franch, A., Castell, M., Perez-Cano, F. J., Bräuer, R., Pohlers, D., et al. (2010). Liposomal encapsulation enhances and prolongs the anti-inflammatory effects of water-soluble dexamethasone phosphate in experimental adjuvant arthritis. Arthritis Res. Ther. 12 (4), R147. doi:10.1186/ar3089
Bai, J., Zhang, Y., Zheng, X., Huang, M., Cheng, W., Shan, H., et al. (2020). LncRNA MM2P-induced, exosome-mediated transfer of Sox9 from monocyte-derived cells modulates primary chondrocytes. Cell Death Dis. 11 (9), 763. doi:10.1038/s41419-020-02945-5
Bedingfield, S. K., Colazo, J. M., Di Francesco, M., Yu, F., Liu, D. D., Di Francesco, V., et al. (2021). Top-down fabricated microPlates for prolonged, intra-articular matrix metalloproteinase 13 siRNA nanocarrier delivery to reduce post-traumatic osteoarthritis. ACS Nano 15 (9), 14475–14491. doi:10.1021/acsnano.1c04005
Bedingfield, S. K., Colazo, J. M., Yu, F., Liu, D. D., Jackson, M. A., Himmel, L. E., et al. (2021). Amelioration of post-traumatic osteoarthritis via nanoparticle depots delivering small interfering RNA to damaged cartilage. Nat. Biomed. Eng. 5 (9), 1069–1083. doi:10.1038/s41551-021-00780-3
Bi, R., Chen, K., Wang, Y., Luo, X., Li, Q., Li, P., et al. (2022). Regulating fibrocartilage stem cells via TNF-α/nf-κb in TMJ osteoarthritis. J. Dent. Res. 101 (3), 312–322. doi:10.1177/00220345211037248
Blagus, T., Markelc, B., Cemazar, M., Kosjek, T., Preat, V., Miklavcic, D., et al. (2013). In vivo real-time monitoring system of electroporation mediated control of transdermal and topical drug delivery. J. Control. Release 172 (3), 862–871. doi:10.1016/j.jconrel.2013.09.030
Brown, S. B., Wang, L., Jungels, R. R., and Sharma, B. (2020). Effects of cartilage-targeting moieties on nanoparticle biodistribution in healthy and osteoarthritic joints. Acta Biomater. 101, 469–483. doi:10.1016/j.actbio.2019.10.003
Cao, Y., Ma, Y., Tao, Y., Lin, W., and Wang, P. (2021). Intra-articular drug delivery for osteoarthritis treatment. Pharmaceutics 13 (12), 2166. doi:10.3390/pharmaceutics13122166
Chen, M. H., Lee, C. H., Liang, H. K., Huang, S. C., Li, J. P., Lin, C. J., et al. (2022). Integrating the microneedles with carboplatin to facilitate the therapeutic effect of radiotherapy for skin cancers. Biomater. Adv. 141, 213113. doi:10.1016/j.bioadv.2022.213113
Cigerim, L., and Kaplan, V. (2020). Analgesic efficacy of naproxen-codeine, naproxen+dexamethasone, and naproxen on myofascial pain: A randomized double-blind controlled trial. Cranio, 1–7. doi:10.1080/08869634.2020.1824411
Clay, C. D., Strait, R. T., Mahler, A., Khodoun, M. V., and Finkelman, F. D. (2018). Anti-FcγRIIB mAb suppresses murine IgG-dependent anaphylaxis by Fc domain targeting of FcγRIII. J. Allergy Clin. Immunol. 141 (4), 1373–1381. e1375. doi:10.1016/j.jaci.2017.05.027
Clemente-Napimoga, J. T., Moreira, J. A., Grillo, R., de Melo, N. F., Fraceto, L. F., and Napimoga, M. H. (2012). 15d-PGJ2-loaded in nanocapsules enhance the antinociceptive properties into rat temporomandibular hypernociception. Life Sci. 90 (23-24), 944–949. doi:10.1016/j.lfs.2012.04.035
Cullis, P. R., and Hope, M. J. (2017). Lipid nanoparticle systems for enabling gene therapies. Mol. Ther. 25 (7), 1467–1475. doi:10.1016/j.ymthe.2017.03.013
Derwich, M., Lassmann, L., Machut, K., Zoltowska, A., and Pawlowska, E. (2022). General characteristics, biomedical and dental application, and usage of chitosan in the treatment of temporomandibular joint disorders: A narrative review. Pharmaceutics 14 (2), 305. doi:10.3390/pharmaceutics14020305
Ding, D., and Zhu, Q. (2018). Recent advances of PLGA micro/nanoparticles for the delivery of biomacromolecular therapeutics. Mat. Sci. Eng. C Mat. Biol. Appl. 92, 1041–1060. doi:10.1016/j.msec.2017.12.036
Feng, Y., Hu, S., Liu, L., Ke, J., and Long, X. (2021). HMGB1 contributes to osteoarthritis of temporomandibular joint by inducing synovial angiogenesis. J. Oral Rehabil. 48 (5), 551–559. doi:10.1111/joor.13129
Ferreira, N., Masterson, D., Lopes de Lima, R., de Souza Moura, B., Oliveira, A. T., Kelly da Silva Fidalgo, T., et al. (2018). Efficacy of viscosupplementation with hyaluronic acid in temporomandibular disorders: A systematic review. J. Craniomaxillofac. Surg. 46 (11), 1943–1952. doi:10.1016/j.jcms.2018.08.007
Gary, D. J., Puri, N., and Won, Y. Y. (2007). Polymer-based siRNA delivery: Perspectives on the fundamental and phenomenological distinctions from polymer-based DNA delivery. J. Control. Release 121 (1-2), 64–73. doi:10.1016/j.jconrel.2007.05.021
Guilherme, V. A., Ribeiro, L. N. M., Alcântara, A. C. S., Castro, S. R., Rodrigues da Silva, G. H., da Silva, C. G., et al. (2019). Improved efficacy of naproxen-loaded NLC for temporomandibular joint administration. Sci. Rep. 9 (1), 11160. doi:10.1038/s41598-019-47486-w
Ishizuka, S., Tsuchiya, S., Ohashi, Y., Terabe, K., Askew, E. B., Ishizuka, N., et al. (2019). Hyaluronan synthase 2 (HAS2) overexpression diminishes the procatabolic activity of chondrocytes by a mechanism independent of extracellular hyaluronan. J. Biol. Chem. 294 (37), 13562–13579. doi:10.1074/jbc.RA119.008567
Ita, K. (2017). Dissolving microneedles for transdermal drug delivery: Advances and challenges. Biomed. Pharmacother. 93, 1116–1127. doi:10.1016/j.biopha.2017.07.019
Jensen, D. M., Cun, D., Maltesen, M. J., Frokjaer, S., Nielsen, H. M., and Foged, C. (2010). Spray drying of siRNA-containing PLGA nanoparticles intended for inhalation. J. Control. Release 142 (1), 138–145. doi:10.1016/j.jconrel.2009.10.010
Kang, M. L., Ko, J. Y., Kim, J. E., and Im, G. I. (2014). Intra-articular delivery of kartogenin-conjugated chitosan nano/microparticles for cartilage regeneration. Biomaterials 35 (37), 9984–9994. doi:10.1016/j.biomaterials.2014.08.042
Kramer, P. R., Puri, J., and Bellinger, L. L. (2010). Knockdown of Fcγ receptor III in an arthritic temporomandibular joint reduces the nociceptive response in rats. Arthritis Rheum. 62 (10), 3109–3118. doi:10.1002/art.27630
Kulkarni, J. A., Witzigmann, D., Thomson, S. B., Chen, S., Leavitt, B. R., Cullis, P. R., et al. (2021). The current landscape of nucleic acid therapeutics. Nat. Nanotechnol. 16 (6), 630–643. doi:10.1038/s41565-021-00898-0
Li, F. L., Wu, C. B., Sun, H. J., and Zhou, Q. (2021). Comparison of autologous platelet-rich plasma and chitosan in the treatment of temporomandibular joint osteoarthritis: A retrospective cohort study. J. Oral Maxillofac. Surg. 79 (2), 324–332. doi:10.1016/j.joms.2020.09.016
Li, H., Guo, H., Lei, C., Liu, L., Xu, L., Feng, Y., et al. (2019). Nanotherapy in joints: Increasing endogenous hyaluronan production by delivering hyaluronan synthase 2. Adv. Mat. 31 (46), e1904535. doi:10.1002/adma.201904535
Li, Y. T., Jiao, J., Zhang, Y., Huang, C. B., Wang, H. D., Wang, B., et al. (2021). Clinical efficacy of cortex daphnes (zushima) patch in patients with symptomatic knee osteoarthritis: A multicenter non-inferiority randomized controlled clinical trial. Front. Pharmacol. 12, 646310. doi:10.3389/fphar.2021.646310
Li, Z., Zhang, Y., and Feng, N. (2019). Mesoporous silica nanoparticles: Synthesis, classification, drug loading, pharmacokinetics, biocompatibility, and application in drug delivery. Expert Opin. Drug Deliv. 16 (3), 219–237. doi:10.1080/17425247.2019.1575806
Liao, A. H., Shih, C. P., Li, M. W., Lin, Y. C., Chuang, H. C., and Wang, C. H. (2021). Development of thermosensitive poloxamer 407-based microbubble gel with ultrasound mediation for inner ear drug delivery. Drug Deliv. 28 (1), 1256–1271. doi:10.1080/10717544.2021.1938758
Macedo, C. G., Jain, A. K., Franz-Montan, M., Napimoga, M. H., Clemente-Napimoga, J. T., and Gill, H. S. (2017). Microneedles enhance topical delivery of 15-deoxy-Δ(12, 14)-prostaglandin J(2) and reduce nociception in temporomandibular joint of rats. J. Control. Release 265, 22–29. doi:10.1016/j.jconrel.2017.06.031
Madry, H., Gao, L., Rey-Rico, A., Venkatesan, J. K., Müller-Brandt, K., Cai, X., et al. (2020). Thermosensitive hydrogel based on PEO-PPO-PEO poloxamers for a controlled in situ release of recombinant adeno-associated viral vectors for effective gene therapy of cartilage defects. Adv. Mat. 32 (2), e1906508. doi:10.1002/adma.201906508
Mora-Raimundo, P., Lozano, D., Benito, M., Mulero, F., Manzano, M., and Vallet-Regí, M. (2021). Osteoporosis remission and new bone formation with mesoporous silica nanoparticles. Adv. Sci. 8 (16), e2101107. doi:10.1002/advs.202101107
Mora-Raimundo, P., Lozano, D., Manzano, M., and Vallet-Regí, M. (2019). Nanoparticles to knockdown osteoporosis-related gene and promote osteogenic marker expression for osteoporosis treatment. ACS Nano 13 (5), 5451–5464. doi:10.1021/acsnano.9b00241
Morry, J., Ngamcherdtrakul, W., Gu, S., Goodyear, S. M., Castro, D. J., Reda, M. M., et al. (2015). Dermal delivery of HSP47 siRNA with NOX4-modulating mesoporous silica-based nanoparticles for treating fibrosis. Biomaterials 66, 41–52. doi:10.1016/j.biomaterials.2015.07.005
Mountziaris, P. M., Sing, D. C., Chew, S. A., Tzouanas, S. N., Lehman, E. D., Kasper, F. K., et al. (2011). Controlled release of anti-inflammatory siRNA from biodegradable polymeric microparticles intended for intra-articular delivery to the temporomandibular joint. Pharm. Res. 28 (6), 1370–1384. doi:10.1007/s11095-010-0354-9
Mountziaris, P. M., Sing, D. C., Mikos, A. G., and Kramer, P. R. (2010). Intra-articular microparticles for drug delivery to the TMJ. J. Dent. Res. 89 (10), 1039–1044. doi:10.1177/0022034510375286
Mountziaris, P. M., Tzouanas, S. N., Sing, D. C., Kramer, P. R., Kasper, F. K., and Mikos, A. G. (2012). Intra-articular controlled release of anti-inflammatory siRNA with biodegradable polymer microparticles ameliorates temporomandibular joint inflammation. Acta Biomater. 8 (10), 3552–3560. doi:10.1016/j.actbio.2012.06.031
Moura, S., Noro, J., Cerqueira, P., Silva, C., Cavaco-Paulo, A., and Loureiro, A. (2020). Poloxamer 407 based-nanoparticles for controlled release of methotrexate. Int. J. Pharm. 575, 118924. doi:10.1016/j.ijpharm.2019.118924
Murata, N., Takashima, Y., Toyoshima, K., Yamamoto, M., and Okada, H. (2008). Anti-tumor effects of anti-VEGF siRNA encapsulated with PLGA microspheres in mice. J. Control. Release 126 (3), 246–254. doi:10.1016/j.jconrel.2007.11.017
Namiki, Y., Fuchigami, T., Tada, N., Kawamura, R., Matsunuma, S., Kitamoto, Y., et al. (2011). Nanomedicine for cancer: Lipid-based nanostructures for drug delivery and monitoring. Acc. Chem. Res. 44 (10), 1080–1093. doi:10.1021/ar200011r
Phatale, V., Vaiphei, K. K., Jha, S., Patil, D., Agrawal, M., and Alexander, A. (2022). Overcoming skin barriers through advanced transdermal drug delivery approaches. J. Control. Release 351, 361–380. doi:10.1016/j.jconrel.2022.09.025
Prausnitz, M. R., and Langer, R. (2008). Transdermal drug delivery. Nat. Biotechnol. 26 (11), 1261–1268. doi:10.1038/nbt.1504
Qu, F., Geng, R., Liu, Y., and Zhu, J. (2022). Advanced nanocarrier- and microneedle-based transdermal drug delivery strategies for skin diseases treatment. Theranostics 12 (7), 3372–3406. doi:10.7150/thno.69999
Queiroz, M. L. B., Shanmugam, S., Santos, L. N. S., Campos, C. A., Santos, A. M., Batista, M. S., et al. (2020). Microneedles as an alternative technology for transdermal drug delivery systems: A patent review. Expert Opin. Ther. Pat. 30 (6), 433–452. doi:10.1080/13543776.2020.1742324
Raza, K., Kumar, M., Kumar, P., Malik, R., Sharma, G., Kaur, M., et al. (2014). Topical delivery of aceclofenac: Challenges and promises of novel drug delivery systems. Biomed. Res. Int. 2014, 406731. doi:10.1155/2014/406731
Sato, S., and Kawamura, H. (2006). Changes in condylar mobility and radiographic alterations after treatment in patients with non-reducing disc displacement of the temporomandibular joint. Dentomaxillofac. Radiol. 35 (4), 289–294. doi:10.1259/dmfr/92464710
Soutschek, J., Akinc, A., Bramlage, B., Charisse, K., Constien, R., Donoghue, M., et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432 (7014), 173–178. doi:10.1038/nature03121
Talaat, W. M., Haider, M., Kawas, S. A., Kandil, N. G., and Harding, D. R. (2016). Chitosan-based thermosensitive hydrogel for controlled drug delivery to the temporomandibular joint. J. Craniofac. Surg. 27 (3), 735–740. doi:10.1097/SCS.0000000000002588
Tamjidi, F., Shahedi, M., Varshosaz, J., and Nasirpour, A. (2013). Nanostructured lipid carriers (nlc): A potential delivery system for bioactive food molecules. Innovative Food Sci. Emerg. Technol. 19, 29–43. doi:10.1016/j.ifset.2013.03.002
Tang, F., Li, L., and Chen, D. (2012). Mesoporous silica nanoparticles: Synthesis, biocompatibility and drug delivery. Adv. Mat. 24 (12), 1504–1534. doi:10.1002/adma.201104763
Tartaglia, G. M., Gizdulich, A., Farronato, M., Gupta, R. J., and Connelly, S. T. (2020). Electroporation technique for joint pain - pilot feasibility study on TMD patients. Clin. Exp. Dent. Res. 6 (6), 642–649. doi:10.1002/cre2.327
Wang, G., Gao, X., Gu, G., Shao, Z., Li, M., Wang, P., et al. (2017). Polyethylene glycol-poly(ε-benzyloxycarbonyl-l-lysine)-conjugated VEGF siRNA for antiangiogenic gene therapy in hepatocellular carcinoma. Int. J. Nanomedicine 12, 3591–3603. doi:10.2147/IJN.S131078
Wang, M., Han, Y., Yu, X., Liang, L., Chang, H., Yeo, D. C., et al. (2020). Upconversion nanoparticle powered microneedle patches for transdermal delivery of siRNA. Adv. Healthc. Mat. 9 (2), e1900635. doi:10.1002/adhm.201900635
Xu, C., Yu, M., Noonan, O., Zhang, J., Song, H., Zhang, H., et al. (2015). Core-cone structured monodispersed mesoporous silica nanoparticles with ultra-large cavity for protein delivery. Small 11 (44), 5949–5955. doi:10.1002/smll.201501449
Yang, J., Wu, S., Hou, L., Zhu, D., Yin, S., Yang, G., et al. (2020). Therapeutic effects of simultaneous delivery of nerve growth factor mRNA and protein via exosomes on cerebral ischemia. Mol. Ther. Nucleic Acids 21, 512–522. doi:10.1016/j.omtn.2020.06.013
Yang, J., Zhu, Y., Wang, F., Deng, L., Xu, X., and Cui, W. (2020). Microfluidic liposomes-anchored microgels as extended delivery platform for treatment of osteoarthritis. Chem. Eng. J. 400, 126004. doi:10.1016/j.cej.2020.126004
Yang, Z., Shi, J., Xie, J., Wang, Y., Sun, J., Liu, T., et al. (2020). Large-scale generation of functional mRNA-encapsulating exosomes via cellular nanoporation. Nat. Biomed. Eng. 4 (1), 69–83. doi:10.1038/s41551-019-0485-1
Zhang, T., Chen, S., Dou, H., Liu, Q., Shu, G., Lin, J., et al. (2021). Novel glucosamine-loaded thermosensitive hydrogels based on poloxamers for osteoarthritis therapy by intra-articular injection. Mat. Sci. Eng. C Mat. Biol. Appl. 118, 111352. doi:10.1016/j.msec.2020.111352
Keywords: drug delivery, intra-articular injection, transdermal administration, temporomandibular joint, osteoarthritis
Citation: Huang X, Pan X, Xiong X, Zhao Z and Cen X (2022) Drug delivery systems for treatment of temporomandibular joint osteoarthritis. Front. Pharmacol. 13:1054703. doi: 10.3389/fphar.2022.1054703
Received: 27 September 2022; Accepted: 26 October 2022;
Published: 07 November 2022.
Edited by:
Romila Manchanda, Michigan State University, United StatesReviewed by:
Pradeep Kumar, Council of Scientific and Industrial Research (CSIR), IndiaMuhammad Wahab Amjad, University of Pittsburgh, United States
Surendra Nimesh, Central University of Rajasthan, India
Copyright © 2022 Huang, Pan, Xiong, Zhao and Cen. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Xiao Cen, Y2VueEBzY3UuZWR1LmNu
†These authors have contributed equally to this work